Foreign investors have deepened their retreat from South Korean stocks, even as the market has kept climbing to new highs on local inflows and the artificial intelligence boom. Foreigners have sold $11.5 billion of Korean stocks so far in May, on a net basis, according to data compiled by Bloomberg. That has them on track for their third-biggest monthly exit on record, after unprecedented withdraw...
Foreign investors have deepened their retreat from South Korean stocks, even as the market has kept climbing to new highs on local inflows and the artificial intelligence boom. Foreigners have sold $11.5 billion of Korean stocks so far in May, on a net basis, according to data compiled by Bloomberg. That has them on track for their third-biggest monthly exit on record, after unprecedented withdrawals in February and March. Local retail investors, who largely missed last year’s rally, have stepped in to help extend gains in the Kospi . The benchmark index is up 87% this year, beating all global peers tracked by Bloomberg. Korean institutions have been buyers as well. “Foreigners can be quite fickle, especially with fast money like hedge funds, but domestic investors can be a more stable anchor now,” said Vey-Sern Ling , a managing director at Union Bancaire Privee. Bumper results from memory chipmakers Samsung Electronics Co. and SK Hynix Inc. have been a key draw for locals, he added. Read more: World’s Biggest Stock Rally Ignites Speculative Mania in Korea So far this year, overseas funds have pulled nearly $48 billion from Korean stocks, on course for a record annual withdrawal. The outlflow is more than double their sales of equities in India, a market far less directly tied to the AI trade. The foreign exodus from Seoul’s market comes as investors debate whether memory has truly entered a “ supercycle ” or will revert to its typical boom-and-bust pattern. Valuations are not much of a concern, with the Kospi trading at about 8.5 times forward earnings estimates while the S&P 500 Index is at 21 times.
同和药业公告，公司于近日收到美国食品药品监督管理局（FDA）签发的卡格列净原料药注册批准函 DMF First Adequate Letter（FA Letter）。卡格列净是一种钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，临床主要用于治疗2型糖尿病。公司卡格列净产品获得美国 FDA 签发的 FA Letter，表明 FDA 已完成对公司卡格列净原料药 DMF 文件的技术审评，可满足关联制剂客户...
同和药业公告，公司于近日收到美国食品药品监督管理局（FDA）签发的卡格列净原料药注册批准函 DMF First Adequate Letter（FA Letter）。卡格列净是一种钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，临床主要用于治疗2型糖尿病。公司卡格列净产品获得美国 FDA 签发的 FA Letter，表明 FDA 已完成对公司卡格列净原料药 DMF 文件的技术审评，可满足关联制剂客户的 ANDA（Abbrevitive New Drug Application，简略新药申请）申报要求。